Total Payments
$201,759
2024 Payments
$39.16
Companies
30
Transactions
522
Medicare Patients
599
Medicare Billing
$168,338
Payment Breakdown by Category
Other$166,579 (82.6%)
Consulting$13,438 (6.7%)
Food & Beverage$12,028 (6.0%)
Travel$9,624 (4.8%)
Research$89.95 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $163,079 | 98 | 80.8% |
| Consulting Fee | $13,438 | 10 | 6.7% |
| Food and Beverage | $12,028 | 380 | 6.0% |
| Travel and Lodging | $9,624 | 29 | 4.8% |
| Honoraria | $3,500 | 2 | 1.7% |
| Unspecified | $89.95 | 3 | 0.0% |
Payments by Type
General
$201,669
519 transactions
Research
$89.95
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB, Inc. | $65,032 | 114 | $0 (2021) |
| ACADIA Pharmaceuticals Inc | $60,828 | 88 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $33,267 | 26 | $0 (2019) |
| Kyowa Kirin, Inc. | $26,587 | 49 | $0 (2021) |
| US WorldMeds, LLC | $8,198 | 27 | $0 (2019) |
| ARBOR PHARMACEUTICALS, INC. | $2,962 | 17 | $0 (2021) |
| Acorda Therapeutics, Inc | $1,076 | 10 | $0 (2020) |
| Impax Laboratories, Inc. | $428.45 | 22 | $0 (2018) |
| ABBVIE INC. | $427.89 | 20 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $415.61 | 20 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39.16 | 2 | ABBVIE INC. ($39.16) |
| 2023 | $14.52 | 1 | GlaxoSmithKline, LLC. ($14.52) |
| 2022 | $145.94 | 7 | ABBVIE INC. ($68.30) |
| 2021 | $15,572 | 41 | Kyowa Kirin, Inc. ($15,192) |
| 2020 | $13,080 | 69 | Kyowa Kirin, Inc. ($11,376) |
| 2019 | $31,428 | 114 | Teva Pharmaceuticals USA, Inc. ($16,059) |
| 2018 | $47,143 | 110 | UCB, Inc. ($23,559) |
| 2017 | $94,337 | 178 | ACADIA Pharmaceuticals Inc ($56,874) |
All Payment Transactions
522 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/09/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: NEUROSCIENCE | ||||||
| 01/11/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: NEUROSCIENCE | ||||||
| 10/19/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: RESPIRATORY | ||||||
| 12/09/2022 | Amneal Pharmaceuticals LLC | RYTARY (Drug) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: NEUROLOGY | ||||||
| 11/17/2022 | GE HealthCare | — | Food and Beverage | Cash or cash equivalent | $17.67 | General |
| 10/13/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: NEUROSCIENCE | ||||||
| 08/17/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $29.33 | General |
| Category: HYPERHYDROSIS | ||||||
| 05/19/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: NEUROSCIENCE | ||||||
| 03/04/2022 | Sunovion Pharmaceuticals Inc. | KYNMOBI (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: CNS | ||||||
| 02/17/2022 | Avion Pharmaceuticals | Dhivy (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: Parkinson's disease | ||||||
| 11/11/2021 | Kyowa Kirin, Inc. | NOURIANZ (Drug) | Food and Beverage | In-kind items and services | $29.12 | General |
| Category: ADENOSINE A2A RECEPTORS | ||||||
| 10/22/2021 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: NEUROSCIENCE | ||||||
| 10/05/2021 | Kyowa Kirin, Inc. | NOURIANZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,175.00 | General |
| Category: ADENOSINE A2A RECEPTORS | ||||||
| 09/22/2021 | Kyowa Kirin, Inc. | NOURIANZ (Drug) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: ADENOSINE A2A RECEPTORS | ||||||
| 09/22/2021 | Kyowa Kirin, Inc. | NOURIANZ (Drug) | Food and Beverage | In-kind items and services | $6.11 | General |
| Category: ADENOSINE A2A RECEPTORS | ||||||
| 09/01/2021 | Adamas Pharmaceuticals, Inc. | GOCOVRI (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: PD | ||||||
| 08/18/2021 | Sunovion Pharmaceuticals Inc. | KYNMOBI (Drug) | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: CNS | ||||||
| 08/16/2021 | Kyowa Kirin, Inc. | NOURIANZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,175.00 | General |
| Category: ADENOSINE A2A RECEPTORS | ||||||
| 08/12/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $11.57 | General |
| Category: PRIMARY CARE | ||||||
| 08/02/2021 | Kyowa Kirin, Inc. | NOURIANZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,175.00 | General |
| Category: ADENOSINE A2A RECEPTORS | ||||||
| 07/29/2021 | Adamas Pharmaceuticals, Inc. | GOCOVRI (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: PD | ||||||
| 07/29/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: NEUROSCIENCE | ||||||
| 07/28/2021 | Kyowa Kirin, Inc. | NOURIANZ (Drug) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: ADENOSINE A2A RECEPTORS | ||||||
| 07/14/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Gastroenterology | ||||||
| 06/30/2021 | Kyowa Kirin, Inc. | NOURIANZ (Drug) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: ADENOSINE A2A RECEPTORS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, OPEN LABEL, TWO-ARM STUDY TO EVALUATE THE IMPACT OF USING WEARABLE DEVICES IN ADDITION TO STANDARD CLINICAL PRACTICE ON PARKINSON'S SUBJECT SYMPTOMS MANAGEMENT - PHASE 4 | UCB SA | $58.40 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 13 | 38 | $16,910 | $4,231 |
| 2022 | 5 | 76 | 1,360 | $93,747 | $24,906 |
| 2021 | 6 | 175 | 4,800 | $154,953 | $55,942 |
| 2020 | 12 | 335 | 6,443 | $237,916 | $83,259 |
Total Patients
599
Total Services
12,641
Medicare Billing
$168,338
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 38 | $16,910 | $4,231 | 25.0% |
| 97110 | Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | Office | 2022 | 17 | 350 | $26,250 | $9,197 | 35.0% |
| 97140 | Therapy procedure using manual technique, each 15 minutes | Office | 2022 | 17 | 364 | $30,940 | $6,918 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 28 | $12,237 | $3,264 | 26.7% |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | Office | 2022 | 17 | 364 | $15,000 | $3,033 | 20.2% |
| 97035 | Application of ultrasound, each 15 minutes | Office | 2022 | 14 | 254 | $9,320 | $2,494 | 26.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 92 | 177 | $43,848 | $18,169 | 41.4% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2021 | 12 | 3,150 | $18,900 | $12,097 | 64.0% |
| 97110 | Therapeutic exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | Office | 2021 | 18 | 409 | $30,675 | $11,126 | 36.3% |
| 97140 | Manual (physical) therapy techniques to 1 or more regions, each 15 minutes | Office | 2021 | 18 | 416 | $35,360 | $8,376 | 23.7% |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | Office | 2021 | 18 | 405 | $17,375 | $3,713 | 21.4% |
| 97035 | Application of ultrasound to 1 or more areas, each 15 minutes | Office | 2021 | 17 | 243 | $8,795 | $2,462 | 28.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 112 | 250 | $57,324 | $21,302 | 37.2% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2020 | 15 | 4,551 | $27,306 | $17,252 | 63.2% |
| 97110 | Therapeutic exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | Office | 2020 | 19 | 451 | $33,825 | $11,346 | 33.5% |
| 97140 | Manual (physical) therapy techniques to 1 or more regions, each 15 minutes | Office | 2020 | 19 | 458 | $38,930 | $9,233 | 23.7% |
| 95911 | Nerve transmission studies, 9-10 studies | Office | 2020 | 25 | 27 | $18,900 | $5,133 | 27.2% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Office | 2020 | 37 | 87 | $17,400 | $4,069 | 23.4% |
| 95912 | Nerve transmission studies, 11-12 studies | Office | 2020 | 18 | 18 | $10,600 | $4,009 | 37.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 23 | 34 | $7,428 | $3,737 | 50.3% |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | Office | 2020 | 16 | 316 | $13,900 | $2,987 | 21.5% |
| 97035 | Application of ultrasound to 1 or more areas, each 15 minutes | Office | 2020 | 16 | 215 | $7,920 | $2,180 | 27.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 12 | 12 | $3,752 | $1,574 | 42.0% |
| 95851 | Range of motion testing of arm, leg or each spine section | Office | 2020 | 23 | 24 | $632.00 | $437.07 | 69.2% |
About Dr. Enrico Fazzini, DO
Dr. Enrico Fazzini, DO is a Neurology healthcare provider based in Forest Hills, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407883150.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Enrico Fazzini, DO has received a total of $201,759 in payments from pharmaceutical and medical device companies, with $39.16 received in 2024. These payments were reported across 522 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($163,079).
As a Medicare-enrolled provider, Fazzini has provided services to 599 Medicare beneficiaries, totaling 12,641 services with total Medicare billing of $168,338. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Forest Hills, NY
- Active Since 06/27/2006
- Last Updated 01/25/2008
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1407883150
Products in Payments
- Neupro (Drug) $65,091
- NUPLAZID (Drug) $60,828
- AUSTEDO (Drug) $33,233
- NOURIANZ (Drug) $26,587
- Xadago (Drug) $8,073
- Horizant (Drug) $2,962
- INBRIJA (Drug) $1,076
- RYTARY (Drug) $810.84
- INGREZZA (Drug) $356.33
- XEOMIN (Biological) $333.35
- Movantik (Drug) $324.34
- NORTHERA (Drug) $264.78
- OSMOLEX ER (Drug) $234.93
- Duopa (Drug) $217.80
- UBRELVY (Drug) $167.02
- NUEDEXTA (Drug) $154.56
- BOTOX (Biological) $110.48
- MYOBLOC (Biological) $106.37
- VRAYLAR (Drug) $100.57
- KYNMOBI (Drug) $93.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Forest Hills
Dr. Marina Neystat, M.d, M.D
Neurology — Payments: $29,600
Neurology $29,600
Dr. Seniha Inan, Md, MD
Neurology — Payments: $4,071
Neurology $4,071
Dr. Kishan Patel
Neurology — Payments: $2,863
Neurology $2,863
Dr. Carlisle St. Martin, M.d, M.D
Neurology — Payments: $989.93
Neurology $989.93
Yelena Amitina, M.d, M.D
Neurology — Payments: $554.99
Neurology $554.99
Dr. Ira Casson, Md, MD
Neurology — Payments: $428.00
Neurology $428.00